scholarly journals Diseases caused by reactions of T lymphocytes towards incompatible structures of the major histocompatibility complex. VI. Autoantibodies characteristic of systemic lupus erythematosus induced by abnormal T-B cell cooperation across I-E.

1982 ◽  
Vol 155 (5) ◽  
pp. 1555-1560 ◽  
Author(s):  
F M van Rappard-van der Veen ◽  
A G Rolink ◽  
E Gleichmann
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Host Reaction ◽  
Systemic Lupus ◽  
Double Stranded Dna ◽  
Histocompatibility Complex ◽  
Nuclear Antigens ◽  
Hla Dr ◽  
Do So ◽  
Autoantibody Formation

By induction of a suitable graft-vs-host reaction (GVHR) in H-2-different F1 mice, one can induce the production of autoantibodies characteristic of systemic lupus erythematosus (SLE). The purpose of the present study was to define the intra-H-2 differences in the F1 recipients that are capable of triggering this process. A GVHR was induced in [B10.A(2R) x B10.A(4R)]F1 mice by injecting 10(8) lymphocytes from either parental strain. Whereas the donor B10.A(4R) induced a massive formation of autoantibodies to thymocytes, erythrocytes, nuclear antigens, and double-stranded DNA, the donor B10.A(2R) failed to do so. The intra-H-2 genetics of these two parent leads to F1 combinations are such that the observed autoantibody formation after the injection of B10.A(4R) T cells must have been triggered exclusively by the incompatible I-Ek subregion of the [B10.A(2R) x B10.A(4R)]F1 recipients. Because I-E appears to be the murine analogue of HLA-D/DR, this finding is of interest with respect to the increased frequency of certain HLA-DR alleles in SLE patients, as discussed.

scholarly journals HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens.

1987 ◽  
Vol 46 (6) ◽  
pp. 457-462 ◽  
Author(s):  
J S Smolen ◽  
J H Klippel ◽  
E Penner ◽  
M Reichlin ◽  
A D Steinberg ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Nuclear Antigens ◽  
Hla Dr

Major histocompatibility complex genes and susceptibility to systemic lupus erythematosus

1990 ◽  
Vol 33 (10) ◽  
pp. 1542-1553 ◽  
Author(s):  
Zdenka Fronek ◽  
Luika A. Timmerman ◽  
Chester A. Alper ◽  
Bevra H. Hahn ◽  
Kenneth Kalunian ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Major Histocompatibility Complex ◽  
Lupus Erythematosus ◽  
Major Histocompatibility ◽  
Systemic Lupus ◽  
Histocompatibility Complex

Inhibition of Adenovirus DNA Synthesis In Vitro by Sera from Patients with Systemic Lupus Erythematosus

1982 ◽  
Vol 2 (12) ◽  
pp. 1492-1500
Author(s):  
Marshall S. Horwitz ◽  
Beth R. Friefeld ◽  
Harold D. Keiser
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Dna Synthesis ◽  
Lupus Erythematosus ◽  
Inhibitory Activity ◽  
Antinuclear Antibodies ◽  
Dna Binding Protein ◽  
Systemic Lupus ◽  
Double Stranded Dna ◽  
The Individual

Sera containing antinuclear antibodies from patients with systemic lupus erythematosus (SLE) and related disorders were tested for their effect on the synthesis of adenovirus (Ad) DNA in an in vitro replication system. After being heated at 60°C for 1 h, some sera from patients with SLE inhibited Ad DNA synthesis by 60 to 100%. Antibodies to double-stranded DNA were present in 15 of the 16 inhibitory sera, and inhibitory activity copurified with anti-double-stranded DNA in the immunoglobulin G fraction. These SLE sera did not inhibit the DNA polymerases α, β, γ and had no antibody to the 72,000-dalton DNA-binding protein necessary for Ad DNA synthesis. The presence of antibodies to single-stranded DNA and a variety of saline-extractable antigens (Sm, Ha, nRNP, and rRNP) did not correlate with SLE serum inhibitory activity. Methods previously developed for studying the individual steps in Ad DNA replication were used to determine the site of inhibition by the SLE sera that contained antibody to double-stranded DNA. Concentrations of the SLE inhibitor that decreased the elongation of Ad DNA by greater than 85% had no effect on either the initiation of Ad DNA synthesis or the polymerization of the first 26 deoxyribonucleotides.

Systemic Lupus Erythematosus

2019 ◽  
Author(s):  
Kyriakos A. Kirou ◽  
Michael D. Lockshin
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Sun Exposure ◽  
Disease Classification ◽  
Discoid Lupus Erythematosus ◽  
Neurologic Disease ◽  
Systemic Lupus ◽  
Nuclear Antigens ◽  
Key Words Systemic Lupus

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune illness characterized by autoantibodies directed at nuclear antigens that cause clinical and laboratory abnormalities, such as rash, arthritis, leukopenia and thrombocytopenia, alopecia, fever, nephritis, and neurologic disease. Most or all of the symptoms of acute lupus are attributable to immunologic attack on the affected organs. Many complications of long-term disease are attributable to both the disease and its treatment. Intense sun exposure, drug reactions, and infections are circumstances that induce flare; the aim of treatment is to induce remission. This chapter is divided into sections dealing with SLE’s definitions; epidemiology; pathogenesis; disease classification, diagnosis, and differential diagnosis; and treatment. This review contains 10 figures, 12 tables, and 97 references. Key Words: Systemic lupus erythematosus, Dermatomyositis, Sjögren syndrome, rheumatoid arthritis, systemic sclerosis, Discoid lupus erythematosus, truncal psoriasiform, annular polycyclic rash

scholarly journals Repeat Testing of Antibodies and Complements in Systemic Lupus Erythematosus: When Is It Enough?

2018 ◽  
Vol 45 (6) ◽  
pp. 827-834 ◽  
Author(s):  
Thomas C. Raissi ◽  
Carly Hewson ◽  
Janet E. Pope
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Chart Review ◽  
Cost Effective ◽  
Complement C3 ◽  
Systemic Lupus ◽  
Abnormal Result ◽  
Repeat Testing ◽  
Nuclear Antigens ◽  
The Cost

Objective.Patients with systemic lupus erythematosus (SLE) frequently undergo repeat testing for antibodies against extractable nuclear antigens (anti-ENA), but it is not known whether this is necessary or cost-effective. This study characterized the frequencies of changes in anti-ENA, anti–dsDNA, and complement C3 and C4 upon repeat testing.Methods.Chart review was done at one site of 130 patients with SLE enrolled in the 1000 Canadian Faces of Lupus prospective registry with annual antibody and complement testing. We determined the frequency of seroconversion (changes) on the next test and over the entire followup given 1 or multiple consistent results, and the cost to detect these changes.Results.Overall, 89.4% of patients had no changes in anti-ENA screening results from the first available test, 3.3% changed from negative to positive, and 7.3% from positive to negative. Following a single anti-ENA test, 3.9% of negative tests changed to positive and 4.2% of positive changed to negative on the next test. After multiple consistent tests, the frequencies of changes progressively declined. No changes from the first test were observed in anti-dsDNA, C3, and C4 in 60.8%, 83.3%, and 75.4% of patients, respectively. After 2 consistent anti-ENA tests, the cost to detect 1 change was above US$2000.Conclusion.Anti-ENA results change infrequently, especially following 1 or more negative tests. The high cost and lack of evidence that changes affect management suggest that repeating anti-ENA tests routinely is unnecessary. Anti-dsDNA and complements change more frequently after an abnormal result, but less after a normal value.

Systemic Lupus Erythematosus

2019 ◽  
Author(s):  
Kyriakos A. Kirou ◽  
Michael D. Lockshin
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Sun Exposure ◽  
Disease Classification ◽  
Discoid Lupus Erythematosus ◽  
Neurologic Disease ◽  
Systemic Lupus ◽  
Nuclear Antigens ◽  
Key Words Systemic Lupus

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune illness characterized by autoantibodies directed at nuclear antigens that cause clinical and laboratory abnormalities, such as rash, arthritis, leukopenia and thrombocytopenia, alopecia, fever, nephritis, and neurologic disease. Most or all of the symptoms of acute lupus are attributable to immunologic attack on the affected organs. Many complications of long-term disease are attributable to both the disease and its treatment. Intense sun exposure, drug reactions, and infections are circumstances that induce flare; the aim of treatment is to induce remission. This chapter is divided into sections dealing with SLE’s definitions; epidemiology; pathogenesis; disease classification, diagnosis, and differential diagnosis; and treatment. This review contains 10 figures, 12 tables, and 97 references. Key Words: Systemic lupus erythematosus, Dermatomyositis, Sjögren syndrome, rheumatoid arthritis, systemic sclerosis, Discoid lupus erythematosus, truncal psoriasiform, annular polycyclic rash

Sign in / Sign up

Export Citation Format

Share Document